Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia-Reference-Cited by-同舟云学术

Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia

Published:2022-04-11 Issue:8 Volume:69 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Shima Haruko¹^ORCID,Kada Akiko²,Tanizawa Akihiko³^ORCID,Sato Iori⁴^ORCID,Tono Chikako⁵,Ito Masaki⁶,Yuza Yuki⁷,Watanabe Akihiro⁸,Kamibeppu Kiyoko⁴,Uryu Hideko⁹,Koh Katsuyoshi¹⁰,Imai Chihaya¹¹^ORCID,Yoshida Nao¹²^ORCID,Koga Yuhki¹³^ORCID,Fujita Naoto¹⁴^ORCID,Saito Akiko M.²,Adachi Souichi¹⁵,Ishii Eiichi¹⁶,Shimada Hiroyuki¹^ORCID

Affiliation:

1. Department of Pediatrics Keio University School of Medicine Tokyo Japan

2. Clinical Research Center National Hospital Organization Nagoya Medical Center Aichi Japan

3. Sugita Genpaku Memorial Obama Municipal Hospital Fukui Japan

4. Department of Family Nursing, Division of Health Sciences and Nursing, Graduate School of Medicine The University of Tokyo Tokyo Japan

5. Department of Pediatrics Iwate Prefectural Chubu Hospital Iwate Japan

6. Department of Pediatrics Soma General Hospital Fukushima Japan

7. Department of Hematology/Oncology Tokyo Metropolitan Children's Medical Center Tokyo Japan

8. Department of Pediatrics Niigata Cancer Center Hospital Niigata Japan

9. Department of Pediatrics National Center for Global Health and Medicine Tokyo Japan

10. Department of Hematology/Oncology Saitama Children's Medical Center Saitama Japan

11. Department of Pediatrics Niigata University Graduate School of Medical and Dental Sciences Niigata Japan

12. Department of Hematology and Oncology, Children's Medical Center Japanese Red Cross Nagoya First Hospital Aichi Japan

13. Department of Pediatrics, Graduate School of Medical Sciences Kyushu University Fukuoka Japan

14. Department of Pediatrics Hiroshima Red Cross Hospital & Atomic‐Bomb Survivors Hospital Hiroshima Japan

15. Human Health Sciences Kyoto University Kyoto Japan

16. Department of Pediatrics Ehime University Graduate School of Medicine Ehime Japan

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29699

Reference39 articles.

1. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

2. Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial

3. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial

4. How I treat chronic myeloid leukemia in children and adolescents

5. Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I‐BFM Study Group;British Journal of Haematology;2024-05-27

2. Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia;Leukemia & Lymphoma;2024-03-21

3. Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials;Frontiers in Oncology;2023-12-20

4. Front-Line Tyrosine Kinase Inhibitors in Pediatric Chronic Myeloid Leukemia: A Study on Efficacy and Safety;Cancers;2023-07-29

5. Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults;Expert Opinion on Pharmacotherapy;2023-07-27